
Study Finds Wide Pay Gaps in Eye Care
The findings come from an analysis of January 2025 Transparency in Coverage data from four major insurers — Blue Cross Blue Shield, UnitedHealthcare, Cigna, and Aetna — and highlight the inconsistent nature of pricing in eye care.
'Facility prices are negotiated by hospitals, health-system outpatient departments, and large ambulatory surgery centers that wield substantially more market clout than individual ophthalmologists,' said Alexander P. Philips of the Center for Advancing Health Policy Through Research at the Brown University School of Public Health in Providence, Rhode Island. 'Those institutions fold a wide range of fixed costs — real estate, equipment, around-the-clock staffing, and community-benefit obligations — into their rates, so the starting point for negotiation differs dramatically from one organization to the next.'
Philips and Christopher Whaley, PhD, also of the Center for Advancing Health Policy Through Research at Brown University School of Public Health, published their findings on July 3 in JAMA Ophthalmology .
For the analysis, Philips and Whaley looked at more than 740,000 price points for 10 high-volume ophthalmology procedures such as intravitreal injections, iris revision surgery, treatment for severe retinopathy, and laser surgery for postcataract treatment. They found facility fees paid by insurance companies often exceeded professional charges by factors of two to four.
For example, median facility prices for standard cataract surgery ranged from $1521 (Cigna) to $4274 (Aetna), a spread of $2753. In contrast, professional fees for the same procedure showed a much narrower interquartile spread of just $439, from $581 to $1020.
'What a physician can charge is anchored to well-known relative-value schedules that leave less room for maneuver,' Philips said. 'The moment a hospital acquires a previously independent office, the exact same cataract extraction can suddenly carry a separate facility component, widening the gap even further.'
For patients, the result can be unpredictable out-of-pocket costs that can skyrocket depending on where they undergo the procedure. 'Independent clinicians, meanwhile, find it harder to compete, and insurers ultimately load those higher facility payments into premiums,' Philips said.
Blue Cross Blue Shield consistently paid above-market rates, 14% higher for professional fees and 13% higher for facility fees, whereas Aetna showed the most dramatic divergence, with professional fees 54% below average and facility fees 45% above, the researchers found.
'Aetna appears to drive a hard bargain with individual physicians, who usually have limited leverage, while conceding more to large hospital systems that control valuable operating rooms and imaging equipment,' Philips told Medscape Medical News . 'That strategy allows the plan to advertise a lean physician fee schedule to employers, keeping the most visible line item in check, yet still maintain broad hospital networks by paying the premiums those systems demand on the facility side.'
'This pattern can look different across specialties; insurers often deploy distinct, specialty-specific tactics depending on whether hospitals, physician groups, or ancillary providers hold the upper hand,' he added. 'For example, UnitedHealth Group's deep vertical integration through Optum gives it the leverage to align professional and facility payments within its own physician and ambulatory-surgery platform, which produces a negotiation dynamic unlike what we see with Aetna in ophthalmology.'
Geographic Analysis
The study's geographic analysis revealed up to fivefold differences in median facility prices for cataract surgery across states. Outlier states like Connecticut and Alaska had significantly higher prices, potentially due to academic centers or Medicare payment policies, the researchers reported.
Philips and Whaley suggest market dynamics such as insurer-provider negotiations, selective contracting, and vertical integration play a major role in shaping these disparities. For instance, UnitedHealthcare's lower facility fees may reflect its ownership of care delivery assets through Optum, while Cigna's lower prices suggest a strategy of selective contracting with providers willing to accept lower reimbursement in exchange for volume.
The commentary also highlighted the potential of publicly available, insurer-posted data on negotiated prices to empower smaller practices. 'Transparent prices can empower smaller groups or solo practitioners with data for fair negotiations,' the authors wrote. 'Facility revenue can be indirectly critical for ophthalmologists in large departments.'
Still, both the study and commentary stress price alone is not a proxy for value. 'These prices are administrative constructs and may not reflect patient responsibility or the actual cost of care delivery,' the commentary noted.
'Patients should resist the reflex to equate a higher bill with better care. What matters far more is choosing the right setting: The same surgeon can perform a cataract extraction in a physician-owned ASC [ambulatory surgery center] for half of what it would cost in a hospital outpatient department, with no difference in clinical outcome,' Philips said. 'That said, both clinicians and patients have limited leverage to shift markets on their own; real progress depends on policy interventions that rein in unwarranted price dispersion across the system. Awareness helps individuals avoid the worst surprises, but meaningful change will flow from site-neutral payment reforms, tighter antitrust oversight, and transparency rules that expose and discourage outlier prices.'
Transparency Reforms
In an invited commentary, Sean T. Berkowitz, MD, MBA, of the Department of Ophthalmology at Vanderbilt University Medical Center in Nashville, Tennessee, and his coauthors from Cleveland Clinic, Cleveland, emphasized that ophthalmology is uniquely positioned to benefit from transparency reforms due to its high volume of standardized procedures.
However, they cautioned the data may not fully capture the nuances of care delivery. 'Site of service may impact findings,' they wrote. 'The proportion of hospital or ambulatory surgical centers in each network or geographic area may explain the larger variation in facility fees.'
They also warned that increased transparency could have unintended consequences. 'More data on local price variation may incentivize upward price pressure, consolidation, and vertical integration,' according to the authors of the commentary. 'Transparency must be paired with policies that promote competition and protect access.'
The authors of the paper and commentary reported no relevant financial conflicts of interest.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi
We recently published . Hudbay Minerals Inc. (NYSE:HBM) is one of the best-performing stocks on Wednesday. Hudbay Minerals grew its share prices for a second day on Wednesday, up 15.03 percent to close at $11.33 apiece, following an impressive earnings performance and a $600-million investment from Mitsubishi Corp. In its updated report, Hudbay Minerals Inc. (NYSE:HBM) said it swung to a net income attributable to shareholders of $117.7 million from an attributable net loss of $16.5 million in the same period last year, driven by higher gross margins and strong cost control. Revenues increased by 26 percent to $536.4 million from $425.5 million year-on-year. 'With the strong performance in the first half of the year, we are reaffirming our full year consolidated production guidance and are favourably tracking well below our full year consolidated cost guidance for 2025,' said Hudbay Minerals Inc. (NYSE:HBM) President and CEO Peter Kukielski. For the full-year period, the company is targeting to produce between 117,000 and 149,000 tons of copper, as well as 247,500 to 308,000 ounces of gold. In other news, Hudbay Minerals Inc. (NYSE:HBM) was able to raise $600 million in fresh funds from Mitsubishi Corp. after the latter acquired a 30-percent stake in Copper World LLC. Under the agreement, Mitsubishi will pay an upfront cash of $420 million, with the balance to serve as a matching contribution within an 18-month period. While we acknowledge the potential of HBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data